Form 4: Nurix Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Houte Hans Van, Chief Financial Officer of Nurix Therapeutics, Inc., sold 2,845 shares of common stock on July 30, 2026 for $23.38 per share.
Summary
- Option exercise/conversion: acquired 3,750 Common Stock on July 30, 2026; holds 41,342 after (Direct).
- Option exercise/conversion: acquired 2,858 Common Stock on July 30, 2026; holds 44,200 after (Direct).
- Option exercise/conversion: acquired 3,572 Common Stock on July 30, 2026; holds 47,772 after (Direct).
- Open-market sale: disposed of 2,845 Common Stock at $23.38 ($66,524) on July 30, 2026; holds 44,927 after (Direct).
- Option exercise/conversion: disposed of 3,750 Restricted Stock Units on July 30, 2026; holds 11,250 after (Direct).
- Option exercise/conversion: disposed of 2,858 Restricted Stock Units on July 30, 2026; holds 20,009 after (Direct).
- Option exercise/conversion: disposed of 3,572 Restricted Stock Units on July 30, 2026; holds 39,303 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $66,524 of stock on the open market.
Insider Transactions
Houte Hans Van — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-30 | Option exercise/conversion | Common Stock | 3,750 | — | — | 41,342 |
| 2026-07-30 | Option exercise/conversion | Common Stock | 2,858 | — | — | 44,200 |
| 2026-07-30 | Option exercise/conversion | Common Stock | 3,572 | — | — | 47,772 |
| 2026-07-30 | Open-market sale | Common Stock | 2,845 | $23 | $66.5K | 44,927 |
| 2026-07-30 | Option exercise/conversion | Restricted Stock Units | 3,750 | — | — | 11,250 |
| 2026-07-30 | Option exercise/conversion | Restricted Stock Units | 2,858 | — | — | 20,009 |
| 2026-07-30 | Option exercise/conversion | Restricted Stock Units | 3,572 | — | — | 39,303 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-30 | Option exercise/conversion (3,750 shares) |
| 2026-07-30 | Option exercise/conversion (2,858 shares) |
| 2026-07-30 | Option exercise/conversion (3,572 shares) |
| 2026-07-30 | Open-market sale (2,845 shares) |
| 2026-07-30 | Option exercise/conversion (3,750 shares) |
| 2026-07-30 | Option exercise/conversion (2,858 shares) |
| 2026-07-30 | Option exercise/conversion (3,572 shares) |
Keywords
insider transaction, Form 4, NRIX, Nurix Therapeutics, Inc., bearish, Houte Hans Van
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.